HMMR and neoplasm: Although NPI-110 and NPI-106 have not yet been evaluated in cancer models, pre-clinical studies on RHAMM silencing or HA–RHAMM interaction blockade have shown promising results in suppressing tumor invasion and metastasis [24,96].